111 related articles for article (PubMed ID: 6449134)
41. Phase II evaluation of aclacinomycin A (ACM-A, NSC208734) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey G
Am J Clin Oncol; 1983 Apr; 6(2):187-90. PubMed ID: 6572470
[TBL] [Abstract][Full Text] [Related]
42. Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia.
Paciucci PA; Keaveney C; Cuttner J; Holland JF
Cancer Res; 1987 Oct; 47(19):5234-7. PubMed ID: 3476201
[TBL] [Abstract][Full Text] [Related]
43. Aclarubicin: experimental and clinical experience.
Röthig HJ; Kraemer HP; Sedlacek HH
Drugs Exp Clin Res; 1985; 11(2):123-5. PubMed ID: 3915280
[TBL] [Abstract][Full Text] [Related]
44. [Pilot studies with aclacinomycin in patients with breast cancer or gastrointestinal tumors].
Rainer H; Gössinger H; Lenzhofer R; Moser K; Schneeweiss B
Wien Med Wochenschr; 1983; 133(7):183-7. PubMed ID: 6868630
[TBL] [Abstract][Full Text] [Related]
45. Phase I-II evaluation of carminomycin in adults with acute leukemia.
Debusscher L; Malarme M; Bron D; Rozencweig M; Stryckmans P
Eur J Cancer Clin Oncol; 1985 Jan; 21(1):31-4. PubMed ID: 3855751
[TBL] [Abstract][Full Text] [Related]
46. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
Ota K; Ohno R; Shirakawa S; Masaoka T; Okada K; Ohashi Y; Taguchi T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1047-55. PubMed ID: 8210256
[TBL] [Abstract][Full Text] [Related]
47. Phase I-II trial of aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East European Oncology Group (SEEOG) Study.
Kerpel-Fronius S; Gyergyay F; Hindy I; Decker A; Sawinsky I; Fäller K; Mechl Z; Nekulova M; Kolaric K; Tomek R
Oncology; 1987; 44(3):159-63. PubMed ID: 3474571
[TBL] [Abstract][Full Text] [Related]
48. [Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia].
Savchenko VG; Isaev VG; Abakumov EM; Khoroshko ND; Turkina AG; Sokolov AN; Viadro MM; Navashin SM
Antibiot Khimioter; 1992 Jul; 37(7):47-9. PubMed ID: 1456812
[TBL] [Abstract][Full Text] [Related]
49. [New agents in the treatment of leukemia and lymphoma].
Yamada K
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1031-40. PubMed ID: 6347079
[No Abstract] [Full Text] [Related]
50. Current status of Japanese studies with the new anthracycline antibiotic aclacinomycin A.
Oki T; Takeuchi T; Oka S; Umezawa H
Recent Results Cancer Res; 1980; 74():207-16. PubMed ID: 7003659
[TBL] [Abstract][Full Text] [Related]
51. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
Van Echo DA; Wiernik PH; Aisner J
Cancer Clin Trials; 1980; 3(4):325-8. PubMed ID: 6933027
[TBL] [Abstract][Full Text] [Related]
52. [Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
Kawada H; Komatsuda M; Masumoto A; Fukuda R; Watanabe S; Yonekura S; Ichikawa Y; Nagao T; Arimori S
Rinsho Ketsueki; 1993 May; 34(5):667-9. PubMed ID: 8315839
[TBL] [Abstract][Full Text] [Related]
53. Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.
Ohno R; Kimura K; Amaki I; Hirano M; Hoshino A; Ikeda Y; Kimura I; Kobayashi M; Konno K; Majima H
Cancer Chemother Pharmacol; 1987; 20(3):230-4. PubMed ID: 3315282
[TBL] [Abstract][Full Text] [Related]
54. Effects of aclacinomycin-A on murine leukemia.
Nara N; Miyamoto T; Hirashima K; Momoi H
Blood; 1982 Jul; 60(1):188-93. PubMed ID: 6952948
[TBL] [Abstract][Full Text] [Related]
55. [Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma].
Shimazaki C; Fujita N; Nakanishi S; Nishio A; Haruyama H; Nakagawa M; Ijichi H
Gan To Kagaku Ryoho; 1985 Nov; 12(11):2202-7. PubMed ID: 3864396
[TBL] [Abstract][Full Text] [Related]
56. [Experimental study of the antitumor anthracycline antibiotic aclarubicin (aclacinomycin A)].
Egorov LV; Terent'eva TG; Rudneva NA; Egorenko GG; Ivanitskaia LP
Antibiot Med Biotekhnol; 1985 Dec; 30(12):918-27. PubMed ID: 3866512
[TBL] [Abstract][Full Text] [Related]
57. [Effects of single administration of tetrahydropyranyladriamycin (THP) in lymphoid malignancy].
Takagi T; Oguro M; Iwabuchi K
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1450-6. PubMed ID: 6588924
[TBL] [Abstract][Full Text] [Related]
58. [Various induction therapies in older patients with acute myeloid leukemias].
Lutz D
Wien Klin Wochenschr; 1985 Feb; 97(3):137-40. PubMed ID: 3856968
[TBL] [Abstract][Full Text] [Related]
59. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
60. [Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
Hiraoka A; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):93-9. PubMed ID: 9987504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
